Farmaseuttisen kemian laitos
Department of Pharmaceutical Chemistry

Julkaisut 2007 (alustava)
Publications 2007 (preliminary)

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Birichevskaya LL et al. A comparison of enzymatic phosphorylation and phosphatidylation of beta-L- and beta-D-nucleosides.
2 Garcia-Horsman JA et al. Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease.
3 Garnier T et al. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
4 Garnier T et al. Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis.
5 Huttunen KM et al. Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.
6 Häkkinen MR et al. Analysis of underivatized polyamines by reversed phase liquid chromatography with electorspray tandem mass spectrometry.
7 Jalkanen AJ et al. Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats.
8 Jarho E. Synthesis, Structure-Activity Relationships and Physico-Chemical Properties of Novel Prolyl Oligopeptidase Inhibitors .
9 Jarho EM et al. 2(S)-(cycloalk-1-enecarbonyl)-1-(4-phenyl-butanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors.
10 Keski-Rahkonen P et al. Quantitative determination of acetylcholine in microdialysis samples using liquid chromatography/atmospheric pressure spray ionization mass spectrometry.
11 Keski-Rahkonen P et al. Determination of tamsulosin in human aqueous humor and serum by liquid chromatography - electrospray ionization tandem mass spectrometry.
12 Kiviranta PH et al. N-(3-(4-hydroxyphenyl)-propenoyl)-amino acid tryptamides as SIRT2 inhibitors.
13 Kokki H et al. Cerebrospinal fluid distribution of ibuprofen after intravenous administration in children.
14 Korhonen LE et al. New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis.
15 Kumpulainen H. Novel Prodrug Structures for Improved Drug Delivery.
16 Kääriäinen TM et al. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
17 Malm TM et al. Pyrrolidine dithiocarbamate activates akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden.
18 Mannila A et al. Plasma and cerebrospinal fluid concentrations of indomethacin in children after intravenous administration.
19 Mannila J. Cyclodextrins in Intraoral Delivery of Delta-9-tetrahydrocannabinol and Cannabidiol .
20 Matero S et al. Predicting the drug concentration in starch acetate matrix tablets from ATR-FTIR spectra using multi-way methods.
21 Mauriala T. Development of LC-MS Methods for Quantitative and Qualitative Analyses of Endogenous Compounds, Drugs and Their Metabolites to Support Drug Discovery Programs .
22 Muhonen P et al. RNA interference tolerates 2´-fluoro modifications at the Argonaute2 cleavage site.
23 Myllymäki MJ et al. Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors.
24 Mönkkönen H et al. Zoledronic acid-induced IPP/ApppI production in vivo.
25 Palomäki VAB et al. Visualization of 2-arachidonoylglycerol accumulation and cannabinoid CB1 receptor activity in rat brain cryosections by functional autoradiography.
26 Purmonen M et al. Molecular dynamics studies on the thermostability of family 11 xylanases.
27 Qu C-J et al. Effects of glucosamine sulfate on intracellular UDP-hexosamine and UDP-glucuronic acid levels in bovine primary chondrocytes.
28 Ribeiro L et al. Aminocarbonyloxymethyl ester prodrugs of flufenamic acid and diclofenac: suppressing the rearrangement pathway in aqueous media.
29 Roivainen J et al. An enzymatic transglycosylation of purine bases.
30 Roivainen J et al. O2,1'-anhydro-(beta-D-psicofuranosyl)thymine and 1-(1',4'-O-anhydro-beta-D-psicofuranosyl)thymine: the crystal structures versus the 1H NMR and ab initio data.
31 Rúnarsson ÖV et al. Antibacterial activity of methylated chitosan and chitooligomer derivatives: synthesis and structure activity relationships.
32 Saario SM, Laitinen JT. Monoglyceride lipase as an enzyme hydrolyzing 2-arachidonoylglycerol.
33 Saario SM, Laitinen JT. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.
34 Sasse BC et al. Hybrid approach for the design of highly affine and selective dopamine D3 receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.
35 Soppi V et al. Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study.
36 Toropainen T et al. Crystal structure changes of gamma-cyclodextrin after the SEDS process in supercritical carbon dioxide affect the dissolution rate of complexed budesonide.
37 Windshügel B et al. Comparison of homology models and X-ray structures of the nuclear receptor CAR: Assessing the structural basis of constitutive activity.
38 Yagodkin A et al. Improved synthesis of trinucleotide phosphoramidites and generation of randomized oligonucleotide libraries.

Farmaseuttisen kemian laitos Department of Pharmaceutical Chemistry
Julkaisutietokanta 16.4.2008 Publications Data Base 16.4.2008